Inventiva (IVA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on the stock and has a $14.00 price target.
Rami Katkhuda’s rating is based on several promising developments surrounding Inventiva’s ongoing clinical trials and financial outlook. The company is making significant progress in its Phase III NATiV3 trial, with over 95% of participants already randomized and enrollment expected to complete by the first half of 2025. This milestone will unlock a substantial €116M tranche of financing, which, along with a $10M milestone payment, is projected to fund operations through the third quarter of 2026.
Additionally, Inventiva has received a positive recommendation from the Data Monitoring Committee to continue the trial without modifications, following a review of safety data from over 1,200 patients. The trial’s focus on lanifibranor, an oral pan-PPAR agonist, in F2/3 MASH patients is noteworthy, with topline results anticipated in the second half of 2026. The extended treatment duration and the inclusion of a patient population that has shown a favorable response in previous studies further bolster the potential success of the trial, positioning lanifibranor ahead of other competitors in the MASH space.